Stay updated on Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial page.

Latest updates to the Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial page
- Check5 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedRevision: v3.4.3 has been added and Revision: v3.4.2 has been removed.SummaryDifference0.0%

- Check27 days agoNo Change Detected
- Check41 days agoChange DetectedAdministrative revision updates were applied: Revision v3.4.2 was added and Revision v3.4.1 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check48 days agoChange DetectedAdded Revision: v3.4.1 and removed the government-funding notice and the earlier Revision: v3.4.0 entry.SummaryDifference0.1%

- Check55 days agoChange DetectedA site-wide notice about a lapse in government funding has been added, informing users that information on the site may not be up to date and that the NIH Clinical Center is open, with links for further details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check62 days agoChange DetectedAdded a glossary display option and updated revision and QC-related labels (Show glossary, Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, Revision: v3.4.0). Removed the older variants of these entries (Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, Revision: v3.3.4).SummaryDifference0.1%

Stay in the know with updates to Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Deucravacitinib Safety/Efficacy in Psoriasis Clinical Trial page.